The current diagnosis of superficial bladder cancer must be reconsidered

Urologia Internationalis

Volumn 69, Issue 2, 2002, Pages 85-90

  Zaak, Dirk ^a   Hofstetter, Alfons ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID;

BLADDER CARCINOMA; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RECURRENCE; CARCINOMA IN SITU; CONFOCAL LASER MICROSCOPY; DEVICE; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; FLUORESCENCE ENDOSCOPY; FOLLOW UP; HUMAN; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SUPERFICIAL CANCER; URINE;

ANTIGENS, NEOPLASM; CYSTOSCOPY; FLUORESCENT DYES; HUMANS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 0036370033     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000065552     Document Type: Review

References (43)

1. Natural history and prognosis of untreated and treated superficial bladder cancer
2. Immediate adjuvant intravesical chemotherapy after transurethral resection of the bladder
3. Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ
4. Current status of urinary cytology in the evaluation of bladder neoplasms
5. Histo-logical typing of urinary bladder tumours
6. The predictive value of flow cytometry and urinary cytology in the follow-up of patients with transitional cell carcinoma of the bladder
7. The significance of bladder quadrant biopsies in patients with primary superficial bladder carcinoma
8. Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer
9. Der wert der transurethralen nachresektion beim oberflächlichen harnblasenkarzinom
10. Prospective study for quality control of TUR of bladder tumors by routine 2nd TUR (ReTUR)
11. Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder
12. Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer
13. Use of diagnostic categories in urinarycytology in comparison with the bladder tumour antigen (BTA) test in bladder cancer patients
14. Can biological markers replace cystoscopy? An update
15. Urinary NMP22 and karyometry in the diagnosis and follow-up of patients with superficial bladder cancer
16. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors
17. Current bladder tumor tests: Does their projected utility fulfill clinical necessity?
18. Diagnosis and treatment of superficial transitional cell carcinoma of the bladder: Facts and perspectives
19. Ultraviolet cystoscopy in patients with bladder cancer
20. Value of in vivo mucosa-staining test with methylene blue in the diagnosis of pretumoral and tumoral lesions of the bladder
21. Fluorescein angiography of the bladder: Technique and relevance to bladder cancer and interstitial cystitis patients
22. Fluorescence diagnosis of porphyrin-marked urothelial tumors: Status of experimental development
23. Intravesical instillation of 5-aminolevulinic acid: The fluorescent metabolite is limited to urothelial cells
24. Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence
25. Clinical evaluation of a method for detecting superficial surgical transitional cell carcinoma of the bladder by light-induced fluorescence of protoporphyrin IX following the topical application of 5-aminolevulinic acid: Preliminary results
26. Clinical results of the transurethreal resection and evaluation of superficial bladder carcinomas by means of fluorescence diagnosis after intravesical instillation of 5-aminolevulinic acid
27. Diagnosis of bladder carcinoma using protoporphyrin IX fluorescence induced by 5-aminolaevulinic acid
28. Fluorescence detection of bladder tumors with 5-aminolevulinic acid
29. Role of 5-aminolevulinic acid in the diagnosis and treatment of superficial bladder cancer: Improvement in diagnostic sensitivity
30. Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid - Results of 1012 fluorescence endoscopies
31. Transurethral resection (TUR) of bladder cancer controlled by 5-aminolevulinic acid induced fluorescence endoscopy (AFE) versus white light endoscopy
32. Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer
33. Decrease of early recurrence by means of 5-aminolevulinic acid-induced fluorescence endoscopy in patients with bladder cancer - Follow-up of a randomized phase III trial
34. Frequent genetic alternations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma
35. Clonality and genetic divergence in multifocal low-grade superficial urothelial carcinoma as determined by chromosome 9 and p53 deletion analysis
36. 5-Aminolevulinic acid-induced fluorescence endoscopy applied at secondary transurethral resection after conventional resection of primary superficial bladder tumors
37. Quantification of 5-aminolevulinic acid induced fluorescence improves the specificity of bladder cancer detection
38. Autofluorescence imaging to optimize 5-ALA-induced fluorescence endoscopy of bladder carcinoma
39. Fluorescence detection of flat bladder carcinoma in situ after intravesical instillation of hypericin
40. Strategien in der bildgebenden diagnostik des harnblasenkarzinoms
41. High resolution imaging of transitional cell carcinoma with optical coherence tomography: Feasibility for the evaluation of bladder pathology
42. In vivo confocal scanning laser microscopy for human skin. Melanin provides strong contrast
43. Near-infrared confocal laser scanning microscopy of bladder tissue in vivo